Exhale

The official blog of the Lung Institute.

Natural Lung Function Decline vs. Lung Function Decline with COPD

27 Apr 2016
| Under COPD | Posted by | 13 Comments
Lung Function Decline with Age vs. COPD

Lung Function with COPD

Lung function naturally declines with age. Aging affects the entire body, including the lungs, and while the majority of the population can extend youthful function through healthy habits, smokers and those with lung diseases, such as COPD, experience the decline at an accelerated rate.

Some age-related changes in the lungs include:

  • Decreases in peak airflow and gas exchange.
  • Decreases in measures of lung function such as vital capacity (the maximum amount of air that can be breathed out following a maximum inhalation).
  • Weakening of the respiratory muscles.
  • Decline in the effectiveness of lung defense mechanisms.

These changes typically do not cause noticeable symptoms in healthy people. Older people might notice difficulty in sustaining vigorous exercise, however, this is typically a combination of heart function decline combined with lung function decline. Those who are obese or smoke are likely to see symptoms of lung function decline sooner than healthier people. Older people are more likely to experience respiratory infections, so getting vaccinations for conditions like influenza and pneumococcal pneumonia are especially important preventative measures.

The most important preventative step, however, is quitting smoking. Smokers are 13 times more likely to develop chronic obstructive pulmonary disease (COPD) than those who have never smoked. A typical middle-aged smoker’s lung age looks like that of someone 10 years older. The single best thing a smoker can do to improve their well-being and extend their life is to quit smoking. Take a look at this graph that illustrates various rates of lung function decline.

Lung Function Decline

Lung function decline graph courtesy of American Family Physician. FEV1 is a standard measurement of lung function, and measures the volume of air that a person blows out in a second.

Lung function decline graph courtesy of American Family Physician. FEV1 is a standard measurement of lung function, and measures the volume of air that a person blows out in a second.

Take note that a smoker who quits smoking at age 40 experiences the same average lung function decline as someone who never smoked. This illustrates the importance of quitting smoking today for a better quality of life tomorrow.

For those who have been diagnosed with COPD, there are various stages. Having a severe and progressive lung disease will shorten your lifespan, but this depends on a number of variables, like the overall health of a person. The GOLD System was developed by the Global Initiative for Chronic Obstructive Lung Disease to be used as a measurement system to track the progression of COPD by stages. The various stages in the GOLD System include:

  • Stage 1 – very mild COPD (chronic coughing, coughing up mucus, breathing discomfort, shortness of breath)
  • Stage 2 – moderate COPD (Above symptoms combined with a drop in pulmonary function test results)
  • Stage 3 – severe emphysema / chronic bronchitis (Above symptoms combined with additional issues such as unintended weight loss and frequent respiratory infections)
  • Stage 4 – very severe COPD (Above symptoms with pulmonary function test results below 30 percent and trouble breathing that can be life threatening)

While lung function declines naturally with age, those with COPD experience a much more accelerated rate of decline than those without lung disease. Many COPD sufferers have slowed the progression of their disease following cellular therapy from the Lung Institute. If you or a loved one suffers from COPD, contact one of our patient coordinators today by calling (800) 729-3065 to see if you are a candidate for cellular therapy.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.